Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
Jinnie J RheeJialin HanMaria E Montez-RathGlenn M ChertowPublished in: Diabetes, obesity & metabolism (2024)
Recognizing the potential for residual confounding, selection bias and immortal time bias, commercially insured patients in the United States with T2DM and CKD treated with SGLT-2 inhibitors experienced significantly lower risks of non-fatal myocardial infarction or stroke relative to those treated with GLP-1 receptor agonists.
Keyphrases
- chronic kidney disease
- end stage renal disease
- newly diagnosed
- peritoneal dialysis
- ejection fraction
- heart failure
- human health
- atrial fibrillation
- prognostic factors
- left ventricular
- high intensity
- type diabetes
- adipose tissue
- patient reported outcomes
- insulin resistance
- blood brain barrier
- patient reported
- glycemic control